Ben McGraw, III, PharmD
Executive Chairman of the Board
Dr. McGraw is currently Chairman and CEO of TheraVida, Inc., a specialty pharmaceutical company as well as CEO of Auration Biotech, Inc., a private biotechnology company focused on using growth factors for tissue regeneration. He is on the board of Aerie Pharmaceuticals, a public ophthalmology company, and active in the SPARK program at Stanford University. Previously, Dr. McGraw was on the board of Ista Pharmaceuticals, a public ophthalmology company; Chairman and CEO of Valentis, Inc.; Corporate Vice President, Corporate Development at Allergan, Inc.; and Vice President, Development at Marion Laboratories, Inc. and Marion Merrell Dow, Inc. (now Sanofi US). Dr. McGraw received his B.S. and Doctor of Pharmacy degrees from the University of Tennessee Health Science Center, where he also completed a clinical practice residency.
David Eveleth, PhD
Chief Executive Officer
David Eveleth is the CEO of Trefoil Therapeutics Inc. Prior to this David was a consultant to numerous biotechnology companies as well as an advisory to venture capital groups. Earlier in his career David led the Ophthalmology Medicines Development Group at Pfizer, a franchise that achieved peak revenue of $1.8 billion. He has been involved in or led seven pharmaceutical INDs, the approval of several new drugs, and the approval of two medical devices. David has experience in both biotech and pharmaceuticals with several different companies and across the neuroscience and ophthalmology therapeutic areas including roles in R&D, business development, and portfolio and decision analysis. David received his PhD in Biology from the University of California, Irvine and was a Bank of America/Giannini Foundation fellow prior to joining industry.
Schalon Newton, DM
Chief Business Officer
Dr. Newton has more than thirty years’ experience in the ophthalmic pharmaceutical and medical device sector. Most recently he has been independently advising a number of early stage ophthalmic biopharma and medical device companies on strategic initiatives. Prior to this he was the Vice President, Strategic Marketing & Business Development at Santen Inc., the market leading Japanese ophthalmic company. In this role he was responsible for developing a re-entry strategy for the U.S. market. Dr. Newton held senior management roles in finance, strategy, sales and marketing and business development at Allergan Pharmaceuticals in the U.S., Europe and Japan where he was the president of the Japanese subsidiary. Schalon holds a B.S. degree in Business Administration from California State University, Northridge, an M.B.A. from the University of California at Berkeley, and a doctorate in management from Case Western Reserve University.
Thomas M. Tremblay, RN BSN
Vice President, Clinical Development
Thomas has more than 25 years of experience in pharmaceutical development across a variety of therapeutic areas. Thomas has served at a wide range of primarily small and mid-size companies in senior clinical operations roles during his career, including, Apexigen, KaloBios Pharmaceuticals, and Onyx Pharmaceuticals, and most recently at Hallux Inc. Earlier in his career, he served at Genentech and Titan Pharmaceuticals. Thomas is also currently an adjunct faculty member at San Francisco State University’s College of Extended Learning, Clinical Trials Design and Management Certificate Program, where he teaches classes in Clinical Trials Monitoring, GCP Compliance Audits and FDA Inspections